MS relapses rose with longer Tysabri pregnancy breaks
Key Takeaway
In women with MS, longer breaks from Tysabri around pregnancy were linked to more relapses.
What They Found
Researchers studied 6,341 pregnancies in 4,998 women with MS that began with relapses. Treatment decisions during pregnancy were linked to higher relapse rates during pregnancy and after delivery. Women taking natalizumab (Tysabri) before pregnancy had more relapses when their treatment break was long. Women taking fingolimod (Gilenya) before pregnancy also had more relapses. Compared with stopping treatment, the lowest relapse rate was linked to a B-cell drug (a treatment that targets immune cells) given before pregnancy.
Who Should Care and Why
The study included women whose MS began with relapses and who gave birth. It compared how different treatment plans around pregnancy were linked to relapses. A short break from Tysabri was linked to fewer relapses than stopping treatment. Plans involving interferon beta or glatiramer acetate (Copaxone) were also linked to fewer relapses than stopping treatment. The findings concern relapse rates during pregnancy and after delivery.
Important Considerations
You should know this study looked back at records from 4,998 women and 6,341 pregnancies. It cannot prove that treatment decisions caused the differences in relapse rates. The abstract does not report whether the treatment plans affected babies.
AI-generated summary — for informational purposes only, not medical advice
Categories:
You May Also Like
11/1/2026
Researchers compared blood from people with childhood-onset MS and healthy volunteers. They found DN
Read More
11/1/2026
In 24 people with severe MS, stem cell treatment lowered signs of inflammation and nerve damage for
Read More
11/1/2026
A review of 49 studies finds special brain scans can detect MS-related inflammation, but scan method
Read More
11/1/2026
In a study of 294 pregnancies, MS flare-ups were uncommon after pausing two treatments. Learn what t
Read More
10/9/2026
A mouse study suggests prepared red blood cells may calm MS-like immune attacks. Learn why liver cel
Read More
10/9/2026
See how lab-grown nerve cells move a key protein, why this may matter for nerve health, and why the
Read MoreUnderstanding MS Research
Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like JAMA neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.
However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.
By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.